Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
267 hedge funds and large institutions have $2.51B invested in Genomic Health, Inc. in 2019 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 104 increasing their positions, 70 reducing their positions, and 21 closing their positions.
186% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 21
49% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 70
17% more funds holding
Funds holding: 228 → 267 (+39)
17% more capital invested
Capital invested by funds: $2.14B → $2.51B (+$361M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less call options, than puts
Call options by funds: $4.39M | Put options by funds: $5.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$32.1M |
| 2 |
Man Group
London,
United Kingdom
|
+$21.6M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$21.3M |
| 4 |
BlackRock
New York
|
+$17.7M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$115M |
| 2 |
D.E. Shaw & Co
New York
|
-$5.61M |
| 3 |
Citigroup
New York
|
-$5.39M |
| 4 |
Millennium Management
New York
|
-$4.63M |
| 5 |
HI
HBK Investments
Dallas,
Texas
|
-$4.46M |
GHDX Hedge Fund Activity: Q1 2019 in Review
267 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q1 2019, worth a combined $2.51B — up 17% from $2.14B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new GHDX positions and 21 closed out — a net gain of 39 holders — while 104 added to existing stakes and 70 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $32.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $115M.
- 267 institutional investors held Genomic Health, Inc. (GHDX) as of Q1 2019, up from 228 in Q4 2018.
- Funds reported $2.51B of Genomic Health, Inc. stock for Q1 2019, up 17% quarter-over-quarter.
- 60 funds opened new Genomic Health, Inc. positions in Q1 2019 and 21 closed out, a net change of +39 holders.
- The largest Genomic Health, Inc. buyer in Q1 2019 was Renaissance Technologies, an estimated $32.1M added.
- The largest Genomic Health, Inc. seller in Q1 2019 was Baker Bros. Advisors, an estimated $115M sold.
Based on aggregated 13F filings for Q1 2019.